Proteomics firm Cellzome said this week it has won more than €2.3 million ($3.1 million) in grants funding its participation in three separate research projects.
The funding supports Cellzome’s work in: Blueprint, an EU-funded effort to analyze the epigenome of the hematopoietic system; Orchid, an EU-funded project in which Cellzome will work under the direction of drugmaker GlaxoSmithKline to identify new drug targets in tuberculosis; and a stem cell characterization project the company has undertaken in collaboration with Pfizer, the University of Sheffield, and the stem cell firm Plasticell (see story this issue).
The company will receive €1.2 million for its work on the Blueprint project, €1.1 million for its stem cell research, and an undisclosed amount for its participation in the Orchid project, which, according to Cellzome chief scientific officer David Simmons, will be centered at GSK’s “Open Lab” in Tres Cantos, Spain.
Cellzome will be using its Episphere and Kinobeads chemoproteomics platforms in these projects, as well as mass spec-based proteome-wide screening methods.